18 patents
Utility
Modulators of Myc, Methods of Using the Same, and Methods of Identifying Agents That Modulate Myc
17 Nov 22
Disclosed herein are methods of modulation of the viability of a cell.
Yosef REFAELI, Brian Curtis TURNER
Filed: 20 May 22
Utility
Compositions and Methods for Treating T Cell Exhaustion
28 Jul 22
Provided herein are compositions and methods for treating T cell exhaustion in a subject, by administering a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein) or immune cells treated with a PTD-MYC fusion protein.
Yosef REFAELI, Brian C. Turner, Thomas R. PAYNE
Filed: 13 May 20
Utility
Compositions and Methods for the Cryopreservation of Immune Cells
12 May 22
Provided herein are compositions and methods for the cryopreservation of immune cells, such as peripheral blood mononuclear cells (PBMCs) by pre-treating the cells with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein) prior to freezing.
Yosef REFAELI, Brian C. TURNER, Thomas R. PAYNE
Filed: 7 Apr 20
Utility
Nanoparticle Formulations
31 Mar 22
This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein.
Brian Curtis TURNER, Yosef REFAELI, Gregory Alan BIRD
Filed: 27 Jul 21
Utility
Nanoparticle formulations
14 Sep 21
This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein.
Brian Curtis Turner, Yosef Refaeli, Gregory Alan Bird
Filed: 14 Jan 20
Utility
Enhanced Reconstitution and Autoreconstitution of the Hematopoietic Compartment
17 Jun 21
The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
Brian C. TURNER, Yosef REFAELI, Gregory Alan BIRD
Filed: 18 Feb 21
Utility
Methods and Compositions for the Treatment of Melanoma
29 Apr 21
Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
Yosef REFAELI, Brian C. TURNER, Gregory Alan BIRD
Filed: 9 Nov 20
Utility
Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
23 Mar 21
The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
Brian C. Turner, Yosef Refaeli, Gregory Alan Bird
Filed: 29 Jan 19
Utility
Production and Use of Red Blood Cells
25 Feb 21
The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
Brian C. TURNER, Yosef REFAELI, Gregory A. BIRD
Filed: 1 Sep 20
Utility
Methods and compositions for the treatment of melanoma
14 Dec 20
Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
Filed: 7 Nov 18
Utility
Production and use of red blood cells
28 Sep 20
The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
Brian C. Turner, Yosef Refaeli, Gregory A. Bird
Filed: 5 Jul 17
Utility
Nanoparticle Formulations
15 Jul 20
This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein.
Brian Curtis TURNER, Yosef REFAELI, Gregory Alan BIRD
Filed: 13 Jan 20
Utility
Modulators of Myc, Methods of Using the Same, and Methods of Identifying Agents That Modulate Myc
8 Jul 20
Disclosed herein are methods of modulation of the viability of a cell.
Yosef REFAELI, Brian Curtis TURNER
Filed: 13 Jan 20
Utility
Methods and Compositions for the Treatment of Cancer
20 May 20
Provided herein are methods for adoptive cell transfer for the treatment of cancer, comprising administering a therapeutically effective amount of immune cells having antitumor activity to a subject, wherein the immune cells are contacted with a protein transduction domain (PTD)-MYC fusion polypeptide prior to administration to the subject.
Yosef REFAELI, Brian C. TURNER, Gregory Alan BIRD
Filed: 31 Jul 18
Utility
Antibodies and Processes for Preparing the Same
13 May 20
Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies.
Yosef REFAELI, Brian TURNER
Filed: 9 Oct 19
Utility
Nanoparticle formulations
9 Mar 20
This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein.
Brian Curtis Turner, Yosef Refaeli, Gregory Alan Bird
Filed: 30 Nov 17
Utility
Compositions and methods for modulating an immune response
10 Feb 20
Disclosed herein are methods of modulation of the viability of a cell using fusion proteins comprising a transporter peptide sequence and a MYC polypeptide.
Yosef Refaeli, Brian Curtis Turner
Filed: 26 Sep 17
Utility
Antibodies and processes for preparing the same
14 Oct 19
Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies.
Yosef Refaeli, Brian Turner
Filed: 22 Aug 16
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first